NVO retreats over 2% as technical sell signals persist despite positive Q2 results

Traders Union
All News
Stocks
Novo nordisk slides 2.12% today

Highlights

Novo Nordisk raised its 2026 outlook and reported higher Q2 adjusted profits supported by strong oral Wegovy uptake and GLP-1 therapy momentum.
The company bought back DKK 8.39 billion in shares, launched new obesity trials, declared a $0.58 dividend, and expanded partnerships in AI-driven drug discovery.
Shares of Novo Nordisk remain above key moving averages, but technical signals are mixed with overbought conditions and high intraday volatility, projecting a 5-day range of $46.36 to $49.21.

Profit boost and strategic deals offset by persistent selling pressure

Novo Nordisk reported higher adjusted profits for Q2 2026 and raised its full-year outlook, reflecting strong uptake of its oral Wegovy treatment and continued momentum in GLP-1 therapies. The company accelerated its DKK 15 billion share buyback program, repurchasing 29.9 million B shares for DKK 8.39 billion, and declared a dividend of $0.58 per share with an ex-dividend date of August 17, 2026. Additional developments included the launch of the AMAZE 9 Phase 3 obesity trial for oral Zenagamtide and a strategic partnership with Amazon Web Services to accelerate AI-driven drug discovery, as well as the start of a late-stage oral Wegovy trial and expanded microbiome research, though price action has remained under broader selling pressure.

Anton Kharitonov, expert at Traders Union, notes that Novo Nordisk’s short-term downside pressure comes despite strong Q2 results and a sizable buyback. He sees the technical outlook remaining fragile, with MACD and RSI showing clear sell signals. Valuation risk persists as price action diverges from favorable fundamentals. Sentiment appears overly optimistic, increasing the threat of further selling if support is lost. "Investors should remain defensive — a breakdown below $46.36 could signal deeper correction risk."

Viktoras Karapetjanc, expert at Traders Union, points to Novo Nordisk’s robust Q2 performance and expanded buyback as strong confirmation of business momentum. He believes the bullish structure remains intact above all major averages. Upbeat developments around oral GLP-1 trials and the AI partnership add further upside triggers. The market still offers multiple setups for growth and sector leadership. "I expect further gains if $47.9 resistance breaks — the outlook for innovative therapies supports ongoing strength."

Jainam Mehta, market strategist, assesses Novo Nordisk as consolidating in a tight technical range despite positive fundamental news. He notes the divergence between bullish medium-term structure and short-term momentum weakness. This may provide a tactical entry setup for breakout traders above $47.9. "A confirmed move outside the $46.36–$49.21 band could offer a quick trade opportunity given current volatility."

Bullish structure tested as sell signals and overbought risks emerge

NVO is trading above its 20-, 50-, and 200-day moving averages at $47.05, $47.63, and $46.41, indicating support across all key timeframes. Short-term resistance stands at the Ichimoku Kijun level of $47.9, with immediate support at $47.56. The medium- to long-term technical structure remains bullish. However, momentum signals are mixed: the MACD issues a strong sell signal, the ADX points to a neutral trend, and the RSI is at 49.38 with a "Sell" outlook. The Stochastic RSI is deep in overbought territory at 98.75, the CCI is neutral, and Bull/Bear Power (BBP) at 0.68 suggests buyers dominate intraday but also flags overbought risk. The Awesome Oscillator is neutral. Sell-side momentum is pronounced following the session open, with intraday volatility measured at 2.31%.

Earlier, analysts noted that Novo Nordisk's technical strength and expanding clinical pipeline were supporting a bullish outlook for the stock. The current retracement alongside elevated volatility introduces a new risk dimension, making a decisive move above $47.9 or below $46.36 the key trigger to watch for the next directional trend.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.